Last $3.69 USD
Change Today +0.07 / 1.93%
Volume 2.3M
XOMA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

xoma corp (XOMA) Snapshot

Open
$3.57
Previous Close
$3.62
Day High
$3.76
Day Low
$3.54
52 Week High
03/4/14 - $9.57
52 Week Low
01/22/15 - $3.25
Market Cap
426.1M
Average Volume 10 Days
2.4M
EPS TTM
$-0.84
Shares Outstanding
115.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XOMA CORP (XOMA)

xoma corp (XOMA) Related Bloomberg News

View More Bloomberg News

xoma corp (XOMA) Related Businessweek News

No Related Businessweek News Found

xoma corp (XOMA) Details

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III studies for non-infectious uveitis, Behçet’s uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, cardiovascular disease, Schnitzler syndrome, and other diseases, as well as diseases under the neutrophilic dermatoses designation; and various proof-of-concept studies, including polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. The company’s proprietary products also include XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, it develops ACEON, an angiotensin converting enzyme inhibitor product; FDC1, a perindopril arginine and amlodipine besylate product; and HCD122 and LFA102 programs for the treatment of cancer. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; and Margaux Biologics, Inc. The company was founded in 1981 and is headquartered in Berkeley, California.

180 Employees
Last Reported Date: 11/6/14
Founded in 1981

xoma corp (XOMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $489.3K
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: $417.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $347.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $391.4K
Chief Commercial Officer and Vice President
Total Annual Compensation: $380.0K
Compensation as of Fiscal Year 2013.

xoma corp (XOMA) Key Developments

XOMA Corporation Enters Amendment to Terms of Loan Agreement

On January 9, 2015, XOMA Corporation amended the terms of the loan agreement, by and between the company and Les Laboratoires Servier and Institut de Recherches Servier (jointly referred to as 'Servier), initially entered into on December 30, 2010 and subsequently amended by a consent, transfer, assumption and amendment agreement entered into as of August 12, 2013. On January 9, 2015, the company and Servier, entered into an amendment no. 2 to the loan agreement which provides for a deferral of the repayment to Servier, the company's partner for the development and commercialization of its lead asset gevokizumab, of the 15.0 million in principal previously due in January 2016. The Loan Amendment modifies the maturity date of the loan to January 15, 2018(unless matures earlier subject to certain conditions) from January 15, 2016 and also provides that principal shall be repaid as follows: 3.0 million to be repaid on January 15, 2016, 5.0 million to be repaid on January 15, 2017 and 7.0 million to be repaid on January 15, 2018. All other terms of the loan agreement remain unchanged, including the interest rate calculation, EURIBOR + 2%, and the formula for resetting the interest rate on the 15th of January and July every six months. If the interest rate was reset on January 8, 2015, the rate would be 2.17%. In addition, the company amended the terms of the amended and restated collaboration agreement, by and between the company and Servier, initially entered into on February 14, 2012 and later amended by an Amendment No. 1 thereto. On January 9, 2015, the company and Servier, entered into an amendment No. 2 to the collaboration agreement. Under the collaboration agreement the company was eligible to receive up to approximately 356 million in the aggregate in milestone payments, most of which were denominated in Euros, if the company re-acquires cardiovascular and/or diabetes rights for use in the United States, and approximately 634 million in aggregate milestone payments if the company does not re-acquire those rights. Under the collaboration amendment, the company would be eligible to receive up to 341 million in the aggregate in milestone payments in the event the company re-acquires the cardiovascular and/or diabetes rights for use in the United States and approximately 619 million if the company does not re-acquire those rights. The milestone reductions are related to a very low prevalence indication of which Servier would not have pursued development had these payments been required. All other terms of the collaboration agreement remain unchanged.

XOMA Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 09:30 AM

XOMA Corporation Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 09:30 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: John W. Varian, Chief Executive Officer, President and Director.

XOMA Corporation Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 03:40 PM

XOMA Corporation Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 03:40 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom. Speakers: John W. Varian, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $3.69 USD +0.07

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €7.91 EUR -0.49
BioInvent International AB kr2.72 SEK -0.04
Dyax Corp $16.16 USD +0.17
MorphoSys AG €77.41 EUR +1.72
PDL BioPharma Inc $7.72 USD +0.09
View Industry Companies
 

Industry Analysis

XOMA

Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit www.xoma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.